Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

639
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
639
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

1.4K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

230
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
230
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

395
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
395
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

327
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
327

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gephyrin Neurological Autoimmunity.

Annals of neurology·2026
Same author

Novel methods for neural IgG characterization and validation in autoimmune neurologic disorders.

Journal of immunological methods·2026
Same author

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice.

Annals of clinical and translational neurology·2026
Same author

Population-Based Epidemiology of Autoimmune Seizures and Epilepsies.

Annals of neurology·2026
Same author

Clinical Insights Into CASPR1 and CASPR1/Contactin-1 Complex Autoimmune Nodopathies.

Neurology·2026
Same author

Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies.

Annals of clinical and translational neurology·2025

Related Experiment Video

Updated: Aug 10, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.0K

Paraneoplastic Neurologic Disorders.

Michael Gilligan1,2, Christopher McGuigan2, Andrew McKeon3,4

  • 1Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, MN, USA.

Current Neurology and Neuroscience Reports
|February 13, 2023
PubMed
Summary

Paraneoplastic neurologic disorders are increasingly recognized due to new antibody biomarkers and updated criteria. These advances aid in diagnosis, prognosis, and treatment strategies for these rare neurological conditions.

Keywords:
Autoimmune neurologyDiagnostic criteriaImmune checkpoint inhibitorsParaneoplastic neurologic syndromes

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
08:59

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

10.7K

Related Experiment Videos

Last Updated: Aug 10, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.0K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
08:59

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

10.7K

Area of Science:

  • Neurology
  • Immunology
  • Oncology

Background:

  • Paraneoplastic neurologic disorders (PNDs) are increasingly recognized, with rising incidence linked to improved diagnostic tools.
  • The development of antibody biomarkers has significantly enhanced the identification and understanding of PNDs.

Purpose of the Study:

  • To provide a comprehensive overview of recent advancements in the field of PNDs.
  • To highlight updated diagnostic criteria and novel antibody biomarkers.

Main Methods:

  • Review of current literature on PNDs.
  • Analysis of updated diagnostic criteria and newly characterized antibody biomarkers.
  • Discussion of therapeutic approaches and the impact of immune checkpoint inhibitors.

Main Results:

  • Updated diagnostic criteria offer a more inclusive approach, incorporating clinical presentations and antibody classifications.
  • Novel antibody biomarkers, such as KLHL-11, are being identified, aiding in specific PND diagnoses (e.g., seminoma-associated brainstem encephalitis).
  • Antibody biomarkers increasingly inform prognosis and potential immunotherapy response.

Conclusions:

  • The field of PNDs is rapidly evolving, driven by the discovery of new antibody biomarkers.
  • Enhanced diagnostic capabilities and a better understanding of antibody associations are improving patient outcomes.
  • Therapeutic strategies focus on integrated cancer care and immunotherapy, informed by biomarker data.